{"type":"trials","record":{"id":22338,"source_id":"clinicaltrials-gov","external_id":"NCT04563650","title":"COVID-19 Serology and Immunosenescence","brief_summary":"This study aims to determine how long COVID-19 neutralizing antibodies can be detected in an elderly institutionalized population presenting fragility factors. This study also aims to stratify seroconversion by immunological profiles of the elderly patients residing in the EHPAD. This stratification requires the measurement of immunological marker levels already described in immunosenescence and also involved in the development of certain chronic infectious diseases more common in the elderly population. This analysis will enable the investigators to describe an immunological, clinical and biological profile representing a patient who has developed an immunity against COVID 19. It will also help the investigators to understand the different mechanisms leading to a reduced immune response after a potential administration of a vaccine. Finally, it will help describe the immune profiles of elderly residents who presented with non-severe forms of COVID-19.","overall_status":"Active Not Recruiting","phases":[],"study_type":"INTERVENTIONAL","sponsor":"Centre Hospitalier Universitaire, Amiens","enrollment":98,"countries":["France"],"start_date":"2020-08-29","completion_date":"2026-06-01","last_update_date":"2026-06-15","source_url":"https://clinicaltrials.gov/study/NCT04563650","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-24T01:17:18.351868+00:00","last_seen_at":"2026-09-25T06:15:06.064+00:00","metadata":{"sex":"ALL","acronym":"SERO-CoV-OLD","age_range":"18 Years","comparator":"COVID-19 negative resident","organization":"Centre Hospitalier Universitaire, Amiens","interventions":["blood sample"],"registry_source":"ClinicalTrials.gov","outcome_measures":["titers of COVID-19 neutralising antibodies — day 0","titers of COVID-19 neutralising antibodies — at 3 months","titers of COVID-19 neutralising antibodies — at 6 months","titers of COVID-19 neutralising antibodies — at 9 months"],"design_description":"RANDOMIZED · PARALLEL · SCREENING · NONE","source_has_results":false},"controlled_terms":["Covid19","Geriatric Medicine","Seroconversion","Immunosenescence","blood sample"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: immunosenescence.","quality_checked_at":"2026-09-25T06:15:09.632521+00:00","duplicate_cluster_key":"id:nct04563650","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2020-08-29 to 2026-06-01","comparator":"COVID-19 negative resident","confidence":"structured-source","population":"ALL · 18 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:15:06.073Z","intervention":["blood sample"],"participants":98,"study_design":"RANDOMIZED · PARALLEL · SCREENING · NONE","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["titers of COVID-19 neutralising antibodies — day 0","titers of COVID-19 neutralising antibodies — at 3 months","titers of COVID-19 neutralising antibodies — at 6 months","titers of COVID-19 neutralising antibodies — at 9 months"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"immune-aging","is_published":true,"match_reasons":["Title contains controlled term: immunosenescence.","Abstract contains controlled term: immunosenescence.","Source terminology contains: immunosenescence.","Title supplies longevity context: senescence.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Immune ageing","slug":"immune-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/22338","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}